Lakeshore Biopharma (LSB) Competitors $2.54 -0.06 (-2.31%) (As of 12:15 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends LSB vs. PDSB, CLLS, MNOV, ADAG, ANIX, BCAB, XFOR, IMUX, GNLX, and MISTShould you be buying Lakeshore Biopharma stock or one of its competitors? The main competitors of Lakeshore Biopharma include PDS Biotechnology (PDSB), Cellectis (CLLS), MediciNova (MNOV), Adagene (ADAG), Anixa Biosciences (ANIX), BioAtla (BCAB), X4 Pharmaceuticals (XFOR), Immunic (IMUX), Genelux (GNLX), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry. Lakeshore Biopharma vs. PDS Biotechnology Cellectis MediciNova Adagene Anixa Biosciences BioAtla X4 Pharmaceuticals Immunic Genelux Milestone Pharmaceuticals PDS Biotechnology (NASDAQ:PDSB) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability. Do insiders & institutionals believe in PDSB or LSB? 26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are held by institutional investors. 9.5% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer PDSB or LSB? PDS Biotechnology received 69 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformPDS BiotechnologyOutperform Votes6969.00% Underperform Votes3131.00% Lakeshore BiopharmaN/AN/A Is PDSB or LSB more profitable? Lakeshore Biopharma's return on equity of 0.00% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -129.12% -64.41% Lakeshore Biopharma N/A N/A N/A Does the media favor PDSB or LSB? In the previous week, PDS Biotechnology had 10 more articles in the media than Lakeshore Biopharma. MarketBeat recorded 12 mentions for PDS Biotechnology and 2 mentions for Lakeshore Biopharma. PDS Biotechnology's average media sentiment score of 0.52 beat Lakeshore Biopharma's score of 0.43 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Overall Sentiment PDS Biotechnology Positive Lakeshore Biopharma Neutral Which has more risk and volatility, PDSB or LSB? PDS Biotechnology has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Which has higher valuation and earnings, PDSB or LSB? PDS Biotechnology has higher earnings, but lower revenue than Lakeshore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$42.94M-$1.16-1.72Lakeshore Biopharma$80.82M0.29-$61.09MN/AN/A Do analysts rate PDSB or LSB? PDS Biotechnology presently has a consensus target price of $12.33, indicating a potential upside of 516.67%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe PDS Biotechnology is more favorable than Lakeshore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Lakeshore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPDS Biotechnology beats Lakeshore Biopharma on 10 of the 14 factors compared between the two stocks. Ad Brownstone ResearchShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Click here for full details. Get Lakeshore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeshore BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.65M$6.32B$4.84B$8.73BDividend YieldN/A8.11%7.55%4.07%P/E RatioN/A9.86120.1617.15Price / Sales0.29365.861,324.7790.61Price / CashN/A50.7536.9535.18Price / Book0.299.806.445.89Net Income-$61.09M$150.49M$113.90M$223.24M7 Day Performance4.96%-5.05%0.34%0.60%1 Month Performance-19.37%-4.77%1.55%5.06%1 Year PerformanceN/A30.44%35.97%26.70% Lakeshore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeshore Biopharma0.5974 of 5 stars$2.54-2.3%N/AN/A$23.65M$80.82M0.00773Gap UpPDSBPDS Biotechnology1.8934 of 5 stars$2.98-8.3%N/A-68.0%$109.72MN/A-2.4420Analyst ForecastCLLSCellectis3.5998 of 5 stars$1.97+3.1%N/A-36.2%$109.49M$9.19M-1.52290High Trading VolumeMNOVMediciNova0.6863 of 5 stars$2.23+45.8%N/A+2.8%$109.37M$1M-13.9410Analyst ForecastGap UpHigh Trading VolumeADAGAdagene3.1849 of 5 stars$2.47+2.1%N/A+57.7%$109.35M$18.11M0.00260Positive NewsGap UpANIXAnixa Biosciences3.2718 of 5 stars$3.31-0.6%N/A+5.8%$106.52M$210,000.00-8.495Positive NewsBCABBioAtla2.8189 of 5 stars$2.19-7.6%N/A-4.3%$105.87M$250,000.00-1.2960Short Interest ↓Analyst RevisionXFORX4 Pharmaceuticals4.129 of 5 stars$0.61-7.5%N/A-49.3%$103.36MN/A7.6780Analyst RevisionNews CoverageGap DownIMUXImmunic2.9588 of 5 stars$1.15-6.9%N/A+0.0%$103.14MN/A-0.9370Short Interest ↑GNLXGenelux1.4028 of 5 stars$2.93-2.3%N/A-80.1%$101.19M$8,000.00-3.0510Analyst ForecastGap UpMISTMilestone Pharmaceuticals2.685 of 5 stars$1.88-3.1%N/A-22.7%$100.15M$1M-1.8430Earnings Report Related Companies and Tools Related Companies PDS Biotechnology Competitors Cellectis Competitors MediciNova Competitors Adagene Competitors Anixa Biosciences Competitors BioAtla Competitors X4 Pharmaceuticals Competitors Immunic Competitors Genelux Competitors Milestone Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LSB) was last updated on 11/18/2024 by MarketBeat.com Staff From Our Partners5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
